Tonix Pharmaceuticals Holding CORP Form 4 insider transactions

Director James Treco reports the involuntary sale of 0.02 common stock shares due to fractional shares resulting from a reverse stock split.

Adeoye Y. Olukotun, a director at Tonix Pharmaceuticals, disposed of 0.812 common stock shares due to an involuntary sale of fractional shares following a reverse stock split.

Richard H. Bagger, a director at Tonix Pharmaceuticals, reported an involuntary sale of 0.02 common stock shares due to a reverse stock split.

Bradley Saenger, CFO of Tonix Pharmaceuticals, reports the surrender of shares following a reverse stock split and the grant of stock options.

Gregory M. Sullivan, Chief Medical Officer of Tonix Pharmaceuticals, reports transactions involving common stock and stock options, including an involuntary sale of fractional shares and the grant of new stock options.

Seth Lederman, CEO of Tonix Pharmaceuticals, reports transactions involving common stock and stock options, including involuntary sales of fractional shares and the grant of new options.

Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, reports the acquisition of stock options and the surrender of shares following a reverse stock split.

Siobhan Fogarty, Chief Technology Officer of Tonix Pharmaceuticals, reports the acquisition of stock options.

Director James Treco acquired stock options in Tonix Pharmaceuticals, according to a Form 4 filing.

Carolyn E. Taylor, a director of Tonix Pharmaceuticals, acquired stock options on May 23, 2024, according to a Form 4 filing with the SEC.

Director Richard Stillwell acquired stock options in Tonix Pharmaceuticals Holding Corp. on May 23, 2024.

Director Adeoye Y Olukotun of Tonix Pharmaceuticals Holding Corp. acquired stock options exercisable for 104,621 shares of common stock.

Director David L. Grange acquired stock options in Tonix Pharmaceuticals Holding Corp. on May 23, 2024.

Director Margaret Smith Bell received stock options for 104,621 shares of Tonix Pharmaceuticals, exercisable at $0.1745, according to a Form 4 filing.

Richard H. Bagger, a director of Tonix Pharmaceuticals, acquired stock options for 104,621 shares on May 23, 2024, at an exercise price of $0.1745.

Seth Lederman, CEO of Tonix Pharmaceuticals, files an amendment to a previous statement to correct the exercise price of stock options granted on February 27, 2024.

Tonix Pharmaceuticals CEO Seth Lederman reports the acquisition of millions of stock options with varying exercise prices and vesting schedules.

Bradley Saenger, CFO of Tonix Pharmaceuticals, reports the acquisition of stock options with exercise prices of $0.368 and $0.46.

Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, reports the acquisition of stock options with exercise prices of $0.368 and $0.46.

Gregory M. Sullivan, Chief Medical Officer of Tonix Pharmaceuticals, was granted stock options on February 27, 2024.